Johnson & Johnson (JNJ)

NYSE: JNJ · Real-Time Price · USD
178.13
-0.30 (-0.17%)
At close: Sep 8, 2025, 4:00 PM
178.13
0.00 (0.00%)
Pre-market: Sep 9, 2025, 5:41 AM EDT
-0.17%
Market Cap429.00B
Revenue (ttm)90.63B
Net Income (ttm)22.66B
Shares Out 2.41B
EPS (ttm)9.33
PE Ratio19.08
Forward PE16.34
Dividend$5.20 (2.92%)
Ex-Dividend DateAug 26, 2025
Volume8,382,514
Open177.36
Previous Close178.43
Day's Range176.70 - 179.45
52-Week Range140.68 - 181.16
Beta0.39
AnalystsBuy
Price Target176.43 (-0.95%)
Earnings DateOct 14, 2025

About JNJ

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]

Sector Healthcare
IPO Date Sep 24, 1944
Employees 138,100
Stock Exchange NYSE
Ticker Symbol JNJ
Full Company Profile

Financial Performance

In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $176.43, which is a decrease of -0.95% from the latest price.

Price Target
$176.43
(-0.95% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been...

11 hours ago - Business Wire

Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fires...

13 hours ago - Business Wire

Johnson & Johnson: All-Time Highs In Sight After Raised Guidance And A Technical Breakout

I reiterate my buy rating on JNJ, supported by steady EPS growth, robust free cash flow, and an attractive valuation. Recent quarterly results beat expectations, with management raising guidance and a...

21 hours ago - Seeking Alpha

Johnson & Johnson: A Safe Hold, But Lacking Catalysts To Beat The Market

This company boasts a strong history of dividend growth, making it attractive for income-focused investors. Currently, the stock appears slightly undervalued, but a clear catalyst is needed for it to ...

1 day ago - Seeking Alpha

Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year RAR...

2 days ago - PRNewsWire

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment BARCELONA, Spain , Sept. 6, 2025 /PRNewswire/ -- Johnso...

3 days ago - PRNewsWire

September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog

Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de...

3 days ago - Seeking Alpha

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaq...

5 days ago - Business Wire

Johnson & Johnson (JNJ) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Johnson & Johnson (NYSE:JNJ) 2025 Wells Fargo Healthcare Conference September 3, 2025 11:50 AM EDT Company Participants Tim Schmid - Executive VP & Worldwide Chairman of MedTech Conference Call Parti...

5 days ago - Seeking Alpha

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

5 days ago - Reuters

Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress

VARIPURE demonstrated strong safety outcomes with no incidence of stroke and 99.7% acute effectiveness of the VARIPULSE ™ Platform in nearly 800 enrolled patientsi IRVINE, Calif. , Sept. 2, 2025 /PRNe...

6 days ago - PRNewsWire

New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

MADRID , Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously publ...

8 days ago - PRNewsWire

J&J drops development of combination arthritis drug

Johnson & Johnson said on Thursday it has decided not to proceed with the development of its combination drug in patients with a type of arthritis, after results from a mid-stage trial did not show su...

11 days ago - Reuters

Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.

They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.

Other symbols: ABBVLLYXLV
11 days ago - Barrons

AMDR Applauds Federal Court Decision to Bar Johnson & Johnson's Biosense Webster Unit from Further Violation of Anti-Trust Laws in a Win for Hospitals, Patients, and the Environment

WASHINGTON--(BUSINESS WIRE)--The Association of Medical Device Reprocessors (AMDR) announced that Judge James Selna of the U.S. District Court for the Central District of California has issued a perma...

11 days ago - Business Wire

Best Dividend Aristocrats For September 2025

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...

12 days ago - Seeking Alpha

2 High-Conviction Picks For 7.73% Growth And 4.22% Yield Within A Dividend Portfolio

Through our latest additions of Deutsche Post and Meta Platforms to The Dividend Income Accelerator Portfolio, we have increased the portfolio's sector diversification and global exposure. In addition...

Other symbols: AAPLBLKMETAPEP
13 days ago - Seeking Alpha

Best Dividend Kings: August 2025

Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued...

Other symbols: ABBVABMABTADMAWRBDXBKH
15 days ago - Seeking Alpha

Johnson & Johnson to invest $2B in North Carolina plant as Trump's 250% drug tariffs loom

It's a move to boost its domestic production as President Donald Trump threatens to slap devastating tariffs on pharmaceutical imports.

17 days ago - New York Post

A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs

Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is ...

Other symbols: REGN
18 days ago - CNBC

Johnson & Johnson announces $2 billion investment to boost U.S. manufacturing as tariffs loom

Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump'...

18 days ago - Fast Company

Johnson & Johnson to invest $2 billion in North Carolina to boost US manufacturing

Johnson & Johnson on Thursday committed to invest $2 billion in North Carolina to expand the drugmaker's U.S. manufacturing presence.

19 days ago - Reuters

Back To Basics: Why I Favor Amgen Over Johnson & Johnson

Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absor...

Other symbols: AMGN
25 days ago - Seeking Alpha

10 stocks with recently increased dividends — and why they merit a closer look

Companies that are increasing their dividends are good bets to hold their own during the next economic downturn.

4 weeks ago - Market Watch

August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys

Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow...

Other symbols: AMGNAMZNBACRMCVXDISHD
4 weeks ago - Seeking Alpha